Scarica l'app Stockscreener
24.77
0.69%
0.2032
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.57
Aprire:
$24.6
Volume 24 ore:
5.27M
Relative Volume:
0.13
Capitalizzazione di mercato:
$140.86B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
13.18
EPS:
1.88
Flusso di cassa netto:
$12.44B
1 W Prestazione:
+0.82%
1M Prestazione:
+0.65%
6M Prestazione:
-4.81%
1 anno Prestazione:
-16.59%
Intervallo 1D:
$24.54
$24.79
Intervallo di 1 settimana:
$24.31
$24.96
Portata 52W:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.77 | 139.69B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
755.12 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.27 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
221.76 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.82 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.80 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Bluefin Capital Management LLC Takes $441,000 Position in Pfizer Inc. $PFE - MarketBeat
Blue Rock Wealth Management LLC Purchases New Position in Pfizer Inc. $PFE - MarketBeat
Belpointe Asset Management LLC Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
Jupiter Wealth Management LLC Sells 39,150 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Bought by Glenview Trust co - MarketBeat
Plato Investment Management Ltd Sells 17,407 Shares of Pfizer Inc. $PFE - MarketBeat
Woodline Partners LP Trims Stake in Pfizer Inc. $PFE - MarketBeat
Great Lakes Advisors LLC Has $2.04 Million Position in Pfizer Inc. $PFE - MarketBeat
Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit - TipRanks
FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects - Benzinga
BioNTech and Pfizer strike back against GSK in London - JUVE Patent
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 711,927 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Stock Holdings Raised by Semmax Financial Advisors Inc. - MarketBeat
Logan Capital Management Inc. Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer-Olema Collaboration Targets Metastatic Breast Cancer - MSN
Pfizer Inc. $PFE Shares Acquired by Fred Alger Management LLC - MarketBeat
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Pfizer Inc. $PFE Shares Purchased by UniSuper Management Pty Ltd - MarketBeat
State of Wyoming Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
NewEdge Advisors LLC Has $11.73 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Tourmaline steers CV disease asset into $1.4B Novartis sale - BioCentury
Hancock Whitney Corp Buys 37,646 Shares of Pfizer Inc. $PFE - MarketBeat
Why The Market Is Dangerously Wrong About Pfizer Stock (NYSE:PFE) - Seeking Alpha
Value Recap: Is Pfizer Inc. vulnerable to short sellersSwing Trade & Real-Time Buy Zone Alerts - Lancaster City Council
Pfizer (PFE) Stock Price Prediction: 2025, 2026, 2030 - Benzinga
Pfizer's Prevnar 20 chosen for pneumococcal immunization in British Columbia - MarketScreener
Pfizer Inc. $PFE Shares Bought by Arete Wealth Advisors LLC - MarketBeat
125,694 Shares in Pfizer Inc. $PFE Bought by Caxton Associates LLP - MarketBeat
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula - BioSpace
Pfizer/BioNTech Announce Positive Comirnaty Results Amid Regulatory Limbo - insights.citeline.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults - Benzinga
Pfizer reports new Covid-19 vaccine data after defending the product - Endpoints News
Amid Vaccine Controversy, Pfizer Says New Covid Shots Are Effective - Barron's
Pfizer (PFE) Reports Positive Phase 3 Results For COVID-19 Vaccine In Adults - simplywall.st
Pfizer, BioNTech showcase new data supporting COVID booster - BioPharma Dive
Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula - MarketScreener
Positive Phase 3 data for Pfizer's Comirnaty - MarketScreener
Pfizer Inc. $PFE Shares Acquired by Kestra Investment Management LLC - MarketBeat
Pfizer, BioNTech Report Positive Preliminary Data From Phase 3 Study for Adapted COVID Vaccine - MarketScreener
Temasek Holdings Private Ltd Takes Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, partner BioNTech say updated COVID shot shows better immune response - Reuters
CTC Alternative Strategies Ltd. Purchases Shares of 219,860 Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Guardian Partners Inc. - MarketBeat
Voleon Capital Management LP Raises Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, partner BioNTech says updated COVID shot shows better immune response - MarketScreener
Teza Capital Management LLC Lowers Stock Position in Pfizer Inc. $PFE - MarketBeat
USS Investment Management Ltd Reduces Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Responds to Trump’s Call for COVID-19 Vaccine Evidence by Citing Published Research and Promising More Data Online - geneonline.com
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):